

A SYNTHETIC APPROACH TO THE MARINE SPONGE ALKALOIDS AGELASIMINE A AND AGELASIMINE B[†]

Tohru Saito, Jun Chikazawa, Yuko Nakamura, and Tozo Fujii*



Faculty of Pharmaceutical Sciences, Kanazawa University, Takara-machi, Kanazawa 920, Japan

Abstract—Syntheses of 7-benzyl-*N*⁶,3-dimethyladenine (**1b**) and 7-benzyl-1,2-dihydro-1,3-dimethyladenine (**2b**), selected as models for the marine sponge alkaloids agelasimine A (**1a**) and agelasimine B (**2a**), respectively, have been achieved via four-step routes starting from 3-methyladenine (**7**). The key steps involved are regioselective methylations of 7-benzyl-3-methyladenine (**9**) and 7-benzyl-1,2-dihydro-3-methyladenine (**11**).


Agelasimine A (**1a**) and agelasimine B (**2a**) are novel adenine-related bicyclic diterpenoids isolated by Fathi-Afshar and Allen from the orange sponge *Agelas mauritiana*.¹ Both compounds exhibit a wide range of interesting biological activities such as cytotoxicity, inhibition of adenosine transfer into rabbit erythrocytes, Ca²⁺-channel antagonistic action, α_1 adrenergic blockade, and others.^{1,2} Their chemical structures have been proposed on the basis of interpretation of their spectral data.¹ In an attempt to confirm the correctness of the proposals by chemical synthesis, we sought possible synthetic routes to the *N*(7)-benzyl analogues (**1b** and **2b**) in the present study as preliminaries to total syntheses of **1a** and **2a**.

The first target selected for synthesis was 7-benzyl-*N*⁶,3-dimethyladenine (**1b**). Montgomery and Thomas reported that treatment of either 3-benzyladenine (**3**; R = PhCH₂) or 7-benzyladenine (**4**; R = PhCH₂) with benzyl chloride in AcNMe₂ in the presence of K₂CO₃ at 110°C overnight gave *N*⁶,3,7-tribenzyladenine (**5**).³ The reaction in both cases is likely to have proceeded through the intermediate 3,7-dibenzyladenine (**6**; R¹ = R² =

[†] Dedicated to Professor Edward C. Taylor (Princeton University) on the occasion of his 70th birthday.



Scheme 1



Scheme 2

PhCH₂), since alkylation of either 3-alkyladenines (**3**) or 7-alkyladenines (**4**) is known to produce 3,7-dialkyladenines (**6**).^{3,4} In view of such an assumed preference for *N*⁶-benzylation of **6** (R¹ = R² = PhCH₂), we planned to follow a similar sequence of reactions for synthesis of **1b** (Scheme 1). Treatment of 7-benzyl-3-methyladenine hydrobromide (**8**), prepared from 3-methyladenine (**7**) by benzylation according to the previously reported procedure,^{4c} in hot H₂O with 10% aqueous NaOH gave the free base (**9**·H₂O) [mp 163–163.5°C (decomp)]⁵ in 80% yield. On methylation with MeI in AcNMe₂ at room temperature for 5 h, **9**·H₂O furnished 7-benzyl-*N*⁶,3-dimethyladenine hydriodide (**10**) [mp 229–230°C (decomp)] in 89% yield. Basification of a warm aqueous solution of **10** with 10% aqueous NaOH afforded the desired free base (**1b**) (mp 153–154.5°C)⁶ in 86% yield. The uv spectra⁶ of **1b** in various solvents were similar to those^{3,7} reported for *N*⁶,3,7-trisubstituted adenines. In addition, the above stability of **1b** under alkaline conditions may rule out the possibility that the methylated product from **9**·H₂O was not **10**, but the 1,3-dimethyl or the 3,9-dimethyl analogue that is expected to be very unstable under alkaline conditions.^{8,9}

For the synthesis of the second target (**2b**), **8** was reduced with NaBH₄ in H₂O at room temperature for 30 min. The resulting, unstable oily 1,2-dihydro derivative (**11**)¹⁰ was then methylated with MeI in AcNMe₂ at room temperature for 4.5 h to give the crude salt (**2b**·HI). On treatment with aqueous NaOH, the crude salt provided the desired free base (**2b**) (mp 96–97°C)¹¹ in 15% overall yield (from **8**). The 1,2-dihydro-1,3-dimethyladenine structure was assignable to the free base on the basis of its ¹H nmr spectrum¹¹ in CDCl₃: the nuclear Overhauser effects (4% each) observed for the two *N*-Me signals (at δ 2.90 and 2.91) on irradiation of the C(2)-methylene signal (at δ 4.13) revealed the proximity of these three groups. On reduction with NaBH₄ in 50% aqueous EtOH at room temperature for 20 min, **1b** produced the oily 1,2-dihydro-*N*⁶,3-dimethyl isomer (**12**)¹² in 84% yield.

Finally, the model compounds (**1b**) and (**2b**) thus synthesized were found to bear similarity in ¹H and ¹³C nmr¹³ spectra to agelasimine A and agelasimine B, respectively, supporting the correctness of the substitution patterns of the adenine moieties in structures **1a** and **2a** proposed for these marine sponge alkaloids. Oxidation of **2b** with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in CHCl₃ at room temperature for 10 min, followed by successive treatments with aqueous HCl and 10% aqueous NaOH, gave **1b** in 30% yield. This conversion is analogous to the previously reported transformation⁸ of 1,2-dihydro-1,3-dimethyladenine (**13**) into *N*⁶,3-dimethyladenine (**16**) through **14** and **15** (Scheme 2), but it may be suggestive of a possible biosynthetic pathway to agelasimine A (**1a**) from agelasimine B (**2a**).

REFERENCES

1. R. Fathi-Afshar and T. M. Allen, *Can. J. Chem.*, 1988, **66**, 45.
2. R. Fathi-Afshar, T. M. Allen, C. A. Krueger, D. A. Cook, A. S. Clanachan, R. Vriend, H. P. Baer, and C. E. Cass, *Can. J. Physiol. Pharmacol.*, 1989, **67**, 276.
3. J. A. Montgomery and H. J. Thomas, *J. Heterocycl. Chem.*, 1964, **1**, 115.
4. (a) N. J. Leonard and T. Fujii, *J. Am. Chem. Soc.*, 1963, **85**, 3719; (b) T. Fujii, G. C. Walker, N. J. Leonard, D. C. DeLong, and K. Gerzon, *J. Med. Chem.*, 1979, **22**, 125; (c) T. Fujii, T. Saito, I. Inoue, Y. Kumazawa, and N. J. Leonard, *Chem. Pharm. Bull.*, 1986, **34**, 1821; (d) N. J. Leonard, T. Fujii, and T. Saito, *ibid.*, 1986, **34**, 2037; (e) T. Fujii, T. Saito, I. Inoue, Y. Kumazawa, and K. Tamura, *ibid.*, 1988, **36**, 107, and references cited therein.
5. Satisfactory analytical and/or spectroscopic data were obtained for all new compounds described.
6. Selected spectral data for **1b**: uv $\lambda_{\max}^{\text{MeOH}}$ 227 nm [shoulder (sh)] (ϵ 11000), 287 (17400); $\lambda_{\max}^{\text{H}_2\text{O}}$ (pH 1) 225 (sh) (11000), 285 (17100); $\lambda_{\max}^{\text{H}_2\text{O}}$ (pH 7) 225 (sh) (10900), 284 (17200); $\lambda_{\max}^{\text{H}_2\text{O}}$ (pH 13) 285 (6600); ^1H nmr (CDCl_3) δ : 3.25 [3H, s, N(3)-Me], 3.61 [3H, s, N⁶-Me], 5.74 (2H, s, CH_2Ph), 7.32 (5H, m, CH_2Ph), 7.38 and 7.58 (1H each, s, purine protons); ^{13}C nmr (CDCl_3) δ : 33.9 and 34.7 (two Me's), 49.9 (CH_2), 113.9, 128.0, 128.2, and 128.8 (Ph), 136.7 [C(5)], 137.7 [C(8)], 142.5 [C(4) or C(6)], 145.2 [C(2)], 150.1 [C(6) or C(4)].
7. (a) A. V. El'tsov, Kh. L. Muravich-Aleksandr, and I. Él'-Sakka, *J. Org. Chem. USSR (Engl. Transl.)*, 1973, **9**, 1308; *Zh. Org. Khim.*, 1973, **9**, 1280 (*Chem. Abstr.*, 1973, **79**, 105193z); (b) T. Fujii, T. Saito, and T. Muramoto, *Chem. Pharm. Bull.*, 1983, **31**, 4270.
8. T. Fujii, T. Saito, and T. Nakasaka, *Chem. Pharm. Bull.*, 1983, **31**, 3521.
9. (a) T. Fujii, T. Itaya, T. Saito, K. Mohri, M. Kawanishi, and T. Nakasaka, *Chem. Pharm. Bull.*, 1989, **37**, 1504; (b) T. Fujii, T. Saito, and T. Nakasaka, *ibid.*, 1989, **37**, 3243.
10. A similar reduction of 3-benzyladenine (3: R = PhCH_2) has been reported: Y. Maki, M. Suzuki, and K. Ozeki, *Tetrahedron Lett.*, 1976, 1199.
11. Selected spectral data for **2b**: uv $\lambda_{\max}^{\text{MeOH}}$ 243 nm (sh) (ϵ 8000), 328 (6300); $\lambda_{\max}^{95\% \text{ aq. EtOH}}$ 244 (sh) (7700), 305 (4700); $\lambda_{\max}^{\text{H}_2\text{O}}$ (pH 1) 226 (sh) (11900), 323 (5800); $\lambda_{\max}^{\text{H}_2\text{O}}$ (pH 7) 325 (6000); $\lambda_{\max}^{\text{H}_2\text{O}}$ (pH 13) 243 (7300), 290 (5800); ^1H nmr (CDCl_3) δ : 2.90 and 2.91 (3H each, s, two N-Me's), 4.13 [2H, s, C(2)-H's], 5.55 (2H, s, CH_2Ph), 7.2–7.4 [6H, broad s, C(8)-H and CH_2Ph]; ^{13}C nmr (CDCl_3) δ : 33.0 and 35.1 (two Me's), 49.9 [N(7)- CH_2], 71.1 [C(2)], 107.4 [C(5)], 127.2, 127.8, 128.7 and 136.4 (Ph), 138.1 [C(8)], 154.2 [C(4) or C(6)], 155.1 [C(6) or C(4)].
12. ^1H nmr (CDCl_3) δ : 2.76 and 2.89 (3H each, s, two N-Me's), 4.34 [2H, s, C(2)-H's], 5.34 (2H, s, CH_2Ph), 7.2–7.4 [6H, broad s, C(8)-H and CH_2Ph].
13. Except for signals arising from the N(7)-substituent.

Received, 26th November, 1992